IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their surface. A recent Phase 2 trial revealed that felzartamab, an investigational ...
European regulators recommended a subcutaneous formulation for a key anti-CD38 therapy, offering clinicians and patients more flexible administration options for multiple myeloma.
San Diego, CA (October 25, 2024) — IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their surface. A recent Phase 2 trial revealed ...
Biogen Inc. has announced the initiation of the global Phase 3 PROMINENT study to evaluate the efficacy and safety of its investigational anti-CD38 monoclonal antibody, felzartamab, compared to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results